We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+35.17%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$53.7M
Cap. Flow
-$13.3M
Cap. Flow %
-3.1%
Top 10 Hldgs %
66.36%
Holding
57
New
–
Increased
1
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$5.62M

Top Sells

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$6.6M
2
IMCR icon
Immunocore
IMCR
+$3.81M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.65M
4
HLVX
HilleVax
HLVX
+$2.22M
5
RXRX icon
Recursion Pharmaceuticals
RXRX
+$2.18M

Sector Composition

Rank Sector Weight
1 Healthcare 98.01%
2 Financials 1.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
26
EyePoint Inc
EYPT
$1.2B
$3.8M 0.89%
480,000
– –
IGMS
27
DELISTED
IGM Biosciences
IGMS
$3.52M 0.82%
154,664
– –
AVDL
28
DELISTED
Avadel Pharmaceuticals
AVDL
$3.3M 0.77%
659,409
– –
BLSA
29
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$3.01M 0.7%
300,000
– –
VIRX
30
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.94M 0.69%
689,709
– –
DBTX
31
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$2.77M 0.65%
801,629
– –
IOBT
32
DELISTED
IO Biotech
IOBT
$2.73M 0.64%
1,008,437
– –
ALXO icon
33
ALX Oncology
ALXO
$290M
$2.52M 0.59%
262,786
– –
TNGX icon
34
Tango Therapeutics
TNGX
$4.41B
$2.28M 0.53%
630,000
– –
AMYT
35
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$2.11M 0.49%
304,715
– –
ALBO
36
DELISTED
Albireo Pharma Inc
ALBO
$1.94M 0.45%
100,000
– –
TERN
37
DELISTED
Terns Pharmaceuticals
TERN
$1.7M 0.4%
289,068
– –
VTVT icon
38
vTv Therapeutics
VTVT
$139M
$1.59M 0.37%
40,888
– –
BOLT icon
39
Bolt Biotherapeutics
BOLT
$7.78M
$1.55M 0.36%
52,458
– –
SNCE
40
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$1.45M 0.34%
45,000
– –
EQ icon
41
Equillium
EQ
$133M
$1.37M 0.32%
615,541
– –
ALLK
42
DELISTED
Allakos
ALLK
$1.05M 0.25%
172,089
– –
ELEV
43
DELISTED
Elevation Oncology
ELEV
$939K 0.22%
830,565
– –
KLRS
44
Kalaris Therapeutics
KLRS
$96.8M
$650K 0.15%
3,580
– –
SWTX
45
DELISTED
SpringWorks Therapeutics
SWTX
$633K 0.15%
22,204
– –
BCEL
46
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$623K 0.15%
396,835
– –
SRZN icon
47
Surrozen
SRZN
$301M
$606K 0.14%
20,000
– –
SYRE icon
48
Spyre Therapeutics
SYRE
$9.25B
$465K 0.11%
35,349
– –
NVAX icon
49
CALL
Novavax
NVAX
$1.31B
$426K 0.1%
23,400
– –
NVAX icon
50
Novavax
NVAX
$1.31B
$387K 0.09%
21,244
– –
1
2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q3 2022 Portfolio in Review

As of Q3 2022, Samsara BioCapital held 57 positions worth $429M, up 14% from $375M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Samsara BioCapital withdrew a net $13.3M in Q3 2022, closing 1 position and reducing 6 holdings. Its most notable exit was Recursion Pharmaceuticals, an estimated $2.18M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

Against the trend, Samsara BioCapital added an estimated $5.62M to Syros Pharmaceuticals, Inc. Common Stock.

  • Samsara BioCapital added most to Syros Pharmaceuticals, Inc. Common Stock in Q3 2022, an estimated $5.62M increase.
  • Samsara BioCapital's biggest Q3 2022 reduction was Forma Therapeutics Holdings, Inc. Common Stock, cutting an estimated $6.6M.
  • Samsara BioCapital fully exited Recursion Pharmaceuticals in Q3 2022, selling an estimated $2.18M.
  • Samsara BioCapital's ten largest holdings make up 66% of its $429M portfolio in Q3 2022.
  • Samsara BioCapital opened 0 new positions and closed 1 in Q3 2022.
  • Samsara BioCapital's portfolio value rose 14% quarter-over-quarter to $429M.

Based on Samsara BioCapital's 13F filing for Q3 2022, filed 14 Nov 2022.